Why did Boston Scientific (BSX) stock move recently?

On 7/27/2026, Boston Scientific moved +4.4% — BSX rose on positive clinical trial updates highlighting progress in its pulsed field ablation technology for atrial fibrillation via the FARAFLEX AFib trial. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Boston Scientific (BSX) overvalued or fairly valued?

MarketChacha shows Boston Scientific's valuation in context — a trailing P/E of about 19.8, a forward P/E of about 15.0, a price-to-book of about 3.0 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Boston Scientific's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.65×) from reported figures — education, not a rating.

What is Boston Scientific's revenue?

Boston Scientific reported revenue of $20.1B for FY2025, with net profit of $2.9B, per official filings.

What is the share price of Boston Scientific (BSX)?

Boston Scientific last traded at $50.47 (-1.9% on the day), as of 8/18/2026 — a delayed quote shown for education, not investment advice.

Boston Scientific

BSX · NYSE · Healthcare · United States

Snapshot

TickerBSX

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees59,000

HeadquartersMarlborough, United States

Websitewww.bostonscientific.com

Filings tracked22

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Who owns it

Insiders0.3%
Institutions95.4%
Public & other4.4%

2,202 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.8.95%
Vanguard Capital Management LLC6.70%
State Street Corporation4.84%
Primecap Management Company3.49%
FMR, LLC3.15%
Geode Capital Management, LLC2.31%
Vanguard Portfolio Management LLC2.06%
Shaw D.E. & Co., Inc.1.76%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.65×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend11.2% → 14.4%

Margin has expanded by about 3.2 points — the business is getting more profitable.

Growth qualityrev 19% · PAT 35%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $5.4B · EPS 0.84

Est. earnings growth +4.6%

Next fiscal year

Rev $22.3B · EPS 3.44

Est. earnings growth +4.1%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$20.1B

Net margin

14.4%

ROE

11.9%

Revenue CAGR (2y)

+18.7%

Profit CAGR (2y)

+34.8%

EPS (FY2025)

1.94

Net profit (FY2025)

$2.9B

Ask MarketChacha about BSX

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 27, 2026
BSX rose on positive clinical trial updates highlighting progress in its pulsed field ablation technology for atrial fibrillation via the FARAFLEX AFib trial.
source 1 ↗· confidence: medium

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$20.1B	$2.9B	1.94	14.4%	11.9%
FY2024	$16.7B	$1.8B	1.25	11.0%	8.5%
FY2023	$14.2B	$1.6B	1.07	11.2%	8.3%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$5.4B	$905.0M	0.61	16.6%
2026Q1	$5.2B	$1.3B	0.90	25.7%
2025Q3	$5.1B	$755.0M	0.51	14.9%
2025Q2	$5.1B	$795.0M	0.53	15.7%
2025Q1	$4.7B	$672.0M	0.45	14.4%
2024Q3	$4.2B	$468.0M	0.32	11.1%
2024Q2	$4.1B	$322.0M	0.22	7.8%
2024Q1	$3.9B	$493.0M	0.33	12.8%
2023Q3	$3.5B	$504.0M	0.34	14.3%
2023Q2	$3.6B	$270.0M	0.18	7.5%
2023Q1	$3.4B	$314.0M	0.21	9.3%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC8/3/2026
8-K — Results of operations, Exhibits
SEC7/29/2026material
8-K — Costs from exit/disposal
SEC7/27/2026material
8-K — Other events, Exhibits
SEC5/18/2026material
8-K — Other events, Exhibits
SEC5/18/2026material
8-K — Bylaw/charter change, Shareholder vote results, Exhibits
SEC5/5/2026material
10-Q filing
SEC5/1/2026
8-K — Results of operations, Exhibits
SEC4/22/2026material
8-K — Other events, Exhibits
SEC3/30/2026material
8-K — Material agreement, Termination of agreement, Material financial obligation, Exhibits
SEC2/26/2026material
8-K — Executive/director change, Reg FD disclosure, Other events, Exhibits
SEC2/23/2026material
10-K filing
SEC2/17/2026
8-K — Executive/director change
SEC2/5/2026material
8-K — Results of operations, Exhibits
SEC2/4/2026material
8-K — Reg FD disclosure, Exhibits
SEC1/15/2026material
8-K — Material agreement, Exhibits
SEC1/15/2026material

2025

8-K — Executive/director change, Exhibits
SEC11/19/2025material
10-Q filing
SEC11/3/2025
8-K — Executive/director change
SEC10/23/2025material
8-K — Results of operations, Exhibits
SEC10/22/2025material
8-K — Executive/director change
SEC9/4/2025material
10-Q filing
SEC8/1/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.